Bubu Banini, MD, PhD

• Albert Do
• George Chen
• Joshua Cornman-Homonoff
• Wajahat Mehal
• Xinshou Ouyang

Clinical Trials as Topic; Fatty Liver, Alcoholic; Obesity; Non-alcoholic Fatty Liver Disease; Health Disparate, Minority and Vulnerable Populations

• Exercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-AnalysisChen G, Banini B, Do A, Gunderson C, Zaman S, Lim J. Exercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Genes 2023, 14: 1811. PMID: 37761951, PMCID: PMC10531443, DOI: 10.3390/genes14091811.
• Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategiesAgyapong G, Dashti F, Banini B. Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies. Annals Of The New York Academy Of Sciences 2023, 1526: 16-29. PMID: 37400359, PMCID: PMC10524684, DOI: 10.1111/nyas.15012.
• Mo1555 HEPATIC HYDROTHORAX PORTENDS WORSE INPATIENT OUTCOMES IN PATIENTS WITH DECOMPENSATED CIRRHOSISAsotibe J, Akuna E, Ismail M, Cornman-Homonoff J, Banini B. Mo1555 HEPATIC HYDROTHORAX PORTENDS WORSE INPATIENT OUTCOMES IN PATIENTS WITH DECOMPENSATED CIRRHOSIS. Gastroenterology 2023, 164: s-856. DOI: 10.1016/s0016-5085(23)02982-7.
• New uses for an old remedy: Digoxin as a potential treatment for steatohepatitis and other disordersJamshed F, Dashti F, Ouyang X, Mehal W, Banini B. New uses for an old remedy: Digoxin as a potential treatment for steatohepatitis and other disorders. World Journal Of Gastroenterology 2023, 29: 1824-1837. PMID: 37032732, PMCID: PMC10080697, DOI: 10.3748/wjg.v29.i12.1824.
• The Independent Effect of Exercise on Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic ReviewChen G, Banini B, Do A, Lim J. The Independent Effect of Exercise on Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review. Clinical And Molecular Hepatology 2022, 29: s319-s332. PMID: 36517000, PMCID: PMC10029942, DOI: 10.3350/cmh.2022.0366.
• Digoxin as an emerging therapy in noncardiac diseasesDashti F, Jamshed F, Ouyang X, Mehal W, Banini B. Digoxin as an emerging therapy in noncardiac diseases. Trends In Pharmacological Sciences 2022, 44: 199-203. PMID: 36396496, DOI: 10.1016/j.tips.2022.10.002.
• Editorial: Recent advances in the understanding of hepatocellular carcinogenesisBanini BA, Mehta R, Santhekadur PK. Editorial: Recent advances in the understanding of hepatocellular carcinogenesis. Frontiers In Oncology 2022, 12: 963998. PMID: 35936725, PMCID: PMC9350505, DOI: 10.3389/fonc.2022.963998.
• Hepatic Hydrothorax: An Independent Predictor of Mortality in Cirrhosis? Is the MELD-Na Score Worth Its Salt?Asotibe JC, Banini BA. Hepatic Hydrothorax: An Independent Predictor of Mortality in Cirrhosis? Is the MELD-Na Score Worth Its Salt? Digestive Diseases And Sciences 2022, 67: 4609-4611. PMID: 35534743, DOI: 10.1007/s10620-022-07523-7.
• Derivation and Validation of a Model to Predict Clinically Significant Portal Hypertension Using Transient Elastography and FIB-4Banini BA, Patel S, Yu JW, Kang L, Bailey C, Strife BJ, Siddiqui MS, Patel V, Matherly SC, Lee H, Lewis S, Cherian R, Stravitz RT, Luketic V, Sanyal AJ, Sterling RK. Derivation and Validation of a Model to Predict Clinically Significant Portal Hypertension Using Transient Elastography and FIB-4. Journal Of Clinical Gastroenterology 2022, 57: 189-197. PMID: 34999644, PMCID: PMC9271129, DOI: 10.1097/mcg.0000000000001664.
• Role of candidate gene variants in modulating the risk and severity of alcoholic hepatitisBeaudoin JJ, Liang T, Tang Q, Banini BA, Shah VH, Sanyal AJ, Chalasani NP, Gawrieh S. Role of candidate gene variants in modulating the risk and severity of alcoholic hepatitis. Alcoholism Clinical And Experimental Research 2021, 45: 709-719. PMID: 33616244, PMCID: PMC8076096, DOI: 10.1111/acer.14581.
• Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin‐Like Phospholipase Domain Containing 3–Mediated Acceleration of SteatohepatitisBanini BA, Kumar DP, Cazanave S, Seneshaw M, Mirshahi F, Santhekadur PK, Wang L, Guan HP, Oseini AM, Alonso C, Bedossa P, Koduru SV, Min H, Sanyal AJ. Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin‐Like Phospholipase Domain Containing 3–Mediated Acceleration of Steatohepatitis. Hepatology 2021, 73: 1290-1306. PMID: 33131062, PMCID: PMC8046714, DOI: 10.1002/hep.31609.
• Reply:Banini BA, Alwatari Y, Ogden N, Gershman E, Shah RD, Strife BJ, Shojaee S, Sterling RK. Reply:. Hepatology 2021, 73: 1237-1238. PMID: 32767857, DOI: 10.1002/hep.31512.
• NAFLD-related HCCBanini BA, Sanyal AJ. NAFLD-related HCC. 2021, 149: 143-169. PMID: 33579423, DOI: 10.1016/bs.acr.2020.11.001.
• Pharmacotherapy for Weight loss in cirrhosis: A case series of GLP-1 agonist-associated weight lossJamshed F, Do A, Kelly M, Drozd K, Viana A, Mehal WZ, Banini A
• Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence‐Based Review and GuidanceBanini BA, Alwatari Y, Stovall M, Ogden N, Gershman E, Shah RD, Strife BJ, Shojaee S, Sterling RK. Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence‐Based Review and Guidance. Hepatology 2020, 72: 1851-1863. PMID: 32585037, DOI: 10.1002/hep.31434.
• Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver diseaseKim TH, Banini BA, Asumda FZ, Campbell NA, Hu C, Moser CD, Shire AM, Han S, Ma C, Krishnan A, Mounajjed T, White TA, Gores GJ, LeBrasseur NK, Charlton MR, Roberts LR. Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease. AJP Gastrointestinal And Liver Physiology 2020, 319: g333-g344. PMID: 32683952, PMCID: PMC7509257, DOI: 10.1152/ajpgi.00150.2019.
• The extracellular sulfatase SULF2 promotes liver tumorigenesis by stimulating assembly of a promoter-looping GLI1-STAT3 transcriptional complexCarr RM, Romecin Duran PA, Tolosa EJ, Ma C, Oseini AM, Moser CD, Banini BA, Huang J, Asumda F, Dhanasekaran R, Graham RP, Toruner MD, Safgren SL, Almada LL, Wang S, Patnaik MM, Roberts LR, Fernandez-Zapico ME. The extracellular sulfatase SULF2 promotes liver tumorigenesis by stimulating assembly of a promoter-looping GLI1-STAT3 transcriptional complex. Journal Of Biological Chemistry 2020, 295: 2698-2712. PMID: 31988246, PMCID: PMC7049957, DOI: 10.1074/jbc.ra119.011146.
• Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic SteatohepatitisBanini BA, Cazanave SC, Yates KP, Asgharpour A, Vincent R, Mirshahi F, Le P, Contos MJ, Tonascia J, Chalasani NP, Kowdley KV, McCullough AJ, Behling CA, Schwimmer JB, Lavine JE, Sanyal AJ. Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis. Journal Of Clinical Gastroenterology 2019, 53: 750-758. PMID: 30586008, PMCID: PMC6588507, DOI: 10.1097/mcg.0000000000001142.
• The use of cell free DNA in the diagnosis of HCCBanini BA, Sanyal AJ. The use of cell free DNA in the diagnosis of HCC. Hepatoma Research 2019, 2019: 34. PMID: 31673629, PMCID: PMC6822275, DOI: 10.20517/2394-5079.2019.30.
• Updates on Chronic HBV: Current Challenges and Future GoalsLee HM, Banini BA. Updates on Chronic HBV: Current Challenges and Future Goals. Current Treatment Options In Gastroenterology 2019, 17: 271-291. PMID: 31077059, DOI: 10.1007/s11938-019-00236-3.
• 318 – Haptoglobin 2 Allele is Associated with Increased Risk and Severity of Alcoholic HepatitisBanini B, Chalasani N, Liang T, Liu W, Liu Z, Le P, Mirshahi F, Shah V, Sanyal A. 318 – Haptoglobin 2 Allele is Associated with Increased Risk and Severity of Alcoholic Hepatitis. Gastroenterology 2019, 156: s-1191. DOI: 10.1016/s0016-5085(19)39952-4.
• Vitamin E in Nonalcoholic Fatty Liver DiseaseBanini B, Sanyal A. Vitamin E in Nonalcoholic Fatty Liver Disease. 2019, 311-323. DOI: 10.1007/978-3-030-05315-4_23.
• THU-295-Non-alcoholic fatty liver disease is associated with QTc lengthening in the general populationBanini B, Issa D, Seneshaw M, Siddiqui M, Oseini A, Mirshahi F, Dessie S, Puri P, Aneni E, Blaha M, Budoff M, Rifai M, Szklo M, Nasir K, Sanyal A. THU-295-Non-alcoholic fatty liver disease is associated with QTc lengthening in the general population. Journal Of Hepatology 2019, 70: e290. DOI: 10.1016/s0618-8278(19)30558-4.
• Enlarging Ectopic Thyroid in the Porta HepatisBanini B, Matherly S, Lee H. Enlarging Ectopic Thyroid in the Porta Hepatis. The American Journal Of Gastroenterology 2018, 113: s1356. DOI: 10.14309/00000434-201810001-02433.
• Coagulopathy: Pathophysiology, Evaluation, and TreatmentBanini B, Sanyal A. Coagulopathy: Pathophysiology, Evaluation, and Treatment. 2018, 173-193. DOI: 10.1007/978-3-319-64298-7_15.
• PS-049 Acceleration of NASH in a mouse model provides novel insights on the mechanisms by which I148M PNPLA3 drives steatohepatitisBanini B, Cazanave S, Min H, Kumar D, Santhekadur P, Wang L, Guan H, Seneshaw M, Bedossa P, Oseini A, Mirshahi F, Alonso C, Koduru S, Sanyal A. PS-049 Acceleration of NASH in a mouse model provides novel insights on the mechanisms by which I148M PNPLA3 drives steatohepatitis. Journal Of Hepatology 2018, 68: s28. DOI: 10.1016/s0168-8278(18)30274-5.
• The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver DiseaseCazanave S, Podtelezhnikov A, Jensen K, Seneshaw M, Kumar DP, Min HK, Santhekadur PK, Banini B, Mauro AG, M. Oseini A, Vincent R, Tanis KQ, Webber AL, Wang L, Bedossa P, Mirshahi F, Sanyal AJ. The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease. Scientific Reports 2017, 7: 17193. PMID: 29222421, PMCID: PMC5722878, DOI: 10.1038/s41598-017-17370-6.
• Corrigendum: Treatment of NASH: What Helps Beyond Weight Loss?Banini BA, Sanyal AJ. Corrigendum: Treatment of NASH: What Helps Beyond Weight Loss? The American Journal Of Gastroenterology 2017, 112: 1352-1352. PMID: 28631731, DOI: 10.1038/ajg.2017.187.
• Current and future pharmacologic treatment of nonalcoholic steatohepatitisBanini BA, Sanyal AJ. Current and future pharmacologic treatment of nonalcoholic steatohepatitis. Current Opinion In Gastroenterology 2017, 33: 134-141. PMID: 28346237, PMCID: PMC5491795, DOI: 10.1097/mog.0000000000000356.
• Treatment of NASH: What Helps Beyond Weight Loss?Banini BA, Sanyal AJ. Treatment of NASH: What Helps Beyond Weight Loss? The American Journal Of Gastroenterology 2017, 112: 821. PMID: 28397875, DOI: 10.1038/ajg.2017.83.
• Transcriptional Induction of Periostin by a Sulfatase 2–TGFβ1–SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular CarcinomaChen G, Nakamura I, Dhanasekaran R, Iguchi E, Tolosa EJ, Romecin PA, Vera RE, Almada LL, Miamen AG, Chaiteerakij R, Zhou M, Asiedu MK, Moser CD, Han S, Hu C, Banini BA, Oseini AM, Chen Y, Fang Y, Yang D, Shaleh HM, Wang S, Wu D, Song T, Lee JS, Thorgeirsson SS, Chevet E, Shah VH, Fernandez-Zapico ME, Roberts LR. Transcriptional Induction of Periostin by a Sulfatase 2–TGFβ1–SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma. Cancer Research 2017, 77: 632-645. PMID: 27872089, PMCID: PMC5429157, DOI: 10.1158/0008-5472.can-15-2556.
• SAT-503 Collagen formation and degradation biomarkers identify advanced fibrosis in NASH patientsLuo Y, Charles E, Vincent R, Gagnon R, Oseini A, Banini B, Mirshahi F, Daita K, Christian R, Sanyal A. SAT-503 Collagen formation and degradation biomarkers identify advanced fibrosis in NASH patients. Journal Of Hepatology 2017, 66: s676-s677. DOI: 10.1016/s0168-8278(17)31824-x.
• THU-367 Key molecular signatures of disease development and progression in non-alcoholic fatty liver disease in humansVincent R, Nefedov A, Oseini A, Cazanave S, Webber A, Jensen K, Tanis K, Wang L, Banini B, Kumar D, Min H, Santhekadur P, Seneshaw M, Daita K, Bedossa P, Mirshahi F, Sanyal A. THU-367 Key molecular signatures of disease development and progression in non-alcoholic fatty liver disease in humans. Journal Of Hepatology 2017, 66: s162. DOI: 10.1016/s0168-8278(17)30598-6.
• Nonalcoholic Steatohepatitis (NASH) Has Surpassed Hepatitis C as the Leading Etiology for Listing for Liver Transplant: Implications for NASH in Children and Young AdultsBanini B, Mota M, Behnke M, Sharma A, Sanyal A. Nonalcoholic Steatohepatitis (NASH) Has Surpassed Hepatitis C as the Leading Etiology for Listing for Liver Transplant: Implications for NASH in Children and Young Adults. The American Journal Of Gastroenterology 2016, 111: s339. DOI: 10.14309/00000434-201610001-00755.
• Transient Elastography Use in the Assessment of Cirrhosis in Patients with Non-Alcoholic SteatohepatitisMota M, Banini B, Siddiqui M, Sanyal A. Transient Elastography Use in the Assessment of Cirrhosis in Patients with Non-Alcoholic Steatohepatitis. The American Journal Of Gastroenterology 2016, 111: s449. DOI: 10.14309/00000434-201610001-01030.
• A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancerAsgharpour A, Cazanave SC, Pacana T, Seneshaw M, Vincent R, Banini BA, Kumar DP, Daita K, Min HK, Mirshahi F, Bedossa P, Sun X, Hoshida Y, Koduru SV, Contaifer D, Warncke UO, Wijesinghe DS, Sanyal AJ. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. Journal Of Hepatology 2016, 65: 579-588. PMID: 27261415, PMCID: PMC5012902, DOI: 10.1016/j.jhep.2016.05.005.
• Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver diseaseMota M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism 2016, 65: 1049-1061. PMID: 26997538, PMCID: PMC4931958, DOI: 10.1016/j.metabol.2016.02.014.
• Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment OptionsBanini BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. Clinical Medicine Insights Therapeutics 2016, 8: cmt.s18885. PMID: 28670148, PMCID: PMC5491796, DOI: 10.4137/cmt.s18885.
• SAT-333 Omega-3 Carboxylic Acids, Epanova®, and the Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin®, Improve Steatohepatitis and Fibrosis Scoring in a Mouse Model of Non-Alcoholic SteatohepatitisCazanave S, Banini B, Asgharpour A, Vincent R, Seneshaw M, Kumar D, Mirshahi F, Daita K, Puri P, Oscarsson J, Bedossa P, Sanyal A. SAT-333 Omega-3 Carboxylic Acids, Epanova®, and the Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin®, Improve Steatohepatitis and Fibrosis Scoring in a Mouse Model of Non-Alcoholic Steatohepatitis. Journal Of Hepatology 2016, 64: s685. DOI: 10.1016/s0168-8278(16)01303-9.
• Hepatocellular CarcinomaBanini B, Roberts L. Hepatocellular Carcinoma. 2015, 207-218. DOI: 10.1007/978-3-319-13614-1_22.
• Hepatocellular carcinoma. In Complications of Cirrhosis: Evaluation and Management.Banini BA and Roberts LR. Hepatocellular carcinoma. In Complications of Cirrhosis: Evaluation and Management. Keaveny A and Cardenas A, Editors. Springer 2015.
• Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF SignalingNakamura I, Zakharia K, Banini BA, Mikhail DS, Kim TH, Yang JD, Moser CD, Shaleh HM, Thornburgh SR, Walters I, Roberts LR. Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling. PLOS ONE 2014, 9: e92273. PMID: 24710173, PMCID: PMC3977817, DOI: 10.1371/journal.pone.0092273.
• Transcriptional regulatory network analysis of developing human erythroid progenitors reveals patterns of coregulation and potential transcriptional regulatorsKeller MA, Addya S, Vadigepalli R, Banini B, Delgrosso K, Huang H, Surrey S. Transcriptional regulatory network analysis of developing human erythroid progenitors reveals patterns of coregulation and potential transcriptional regulators. Physiological Genomics 2006, 28: 114-128. PMID: 16940433, DOI: 10.1152/physiolgenomics.00055.2006.
• 53 EARLY EXPOSURE TO BUTYRATE INCREASES FETAL HEMOGLOBIN DURING ADULT ERYTHROID DEVELOPMENT IN VITRO.Banini B, Addya S, Delgrosso K, Keller M, Surrey S. 53 EARLY EXPOSURE TO BUTYRATE INCREASES FETAL HEMOGLOBIN DURING ADULT ERYTHROID DEVELOPMENT IN VITRO. Journal Of Investigative Medicine 2006, 54: s352. DOI: 10.2310/6650.2005.x0015.52.
• Early Exposure to Butyrate Increases Fetal Hemoglobin during Adult Erythroid Development in VitroBanini B, Addya S, Delgrosso K, Keller M, Surrey S. Early Exposure to Butyrate Increases Fetal Hemoglobin during Adult Erythroid Development in Vitro. Journal Of Investigative Medicine 2006, 54: 352-352. DOI: 10.1177/108155890605402s53.
• Transcriptome Analysis of Human Hematopoietic Progenitor Cells during In Vitro Erythroid Differentiation.Keller M, Addya S, Vadigepalli R, Ponte C, Banini B, Delgrosso K, Surrey S. Transcriptome Analysis of Human Hematopoietic Progenitor Cells during In Vitro Erythroid Differentiation. Blood 2005, 106: 1750-1750. DOI: 10.1182/blood.v106.11.1750.1750.